Latest Therapies under investigation for multiple sclerosis Stories
EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US.
PARIS, October 26, 2010 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta). Teriflunomide is a novel oral disease modifier developed by sanofi-aventis which is being investigated in a large Phase III clinical...
PARIS, October 15, 2010 /PRNewswire-FirstCall/ -- - Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).
SILVER SPRING, Md., Sept. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).
EAST HANOVER, N.J., Sept.
ROCKLAND, Mass., July 28 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S.
EAST HANOVER, N.J., June 10 /PRNewswire/ -- Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease.
WALTHAM, Mass., April 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that early lines of therapy for the treatment of multiple sclerosis are dominated by Teva's Copaxone and Biogen Idec's Avonex, an interferon-beta (IFN-beta) agent.
A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.
WALTHAM, Mass., March 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of secondary progressive multiple sclerosis, Biogen Idec/Elan's Tysabri will remain Decision Resources' proprietary clinical gold standard through 2018.
- A serpent whose bite was fabled to produce intense thirst.